ALX Oncology Holdings Inc ALXO:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/08/21 EST
69.59quote price arrow up+0.97 (+1.41%)
Volume
255,749
52 week range
28.01 - 117.45

...

Loading . . .

KEY STATS

  • Open71.87
  • Day High76.73
  • Day Low69.31
  • Prev Close69.59
  • 52 Week High117.45
  • 52 Week High Date12/10/20
  • 52 Week Low28.01
  • 52 Week Low Date07/23/20
  • Market Cap2.748B
  • Shares Out39.49M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.14
  • P/E (TTM)-61.22
  • Fwd P/E (NTM)-43.68
  • EBITDA (MRQ)-33.241M
  • ROE (MRQ)-
  • Revenue (MRQ)2.40M
  • Gross Margin (MRQ)9.06%
  • Net Margin (MRQ)-1,450.10%
  • Debt To Equity (MRQ)2.29%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest ALX Oncology Holdings Inc News

There is no recent news for this security.

Latest ALXO News From Our Partners

QUOTE FINDER

Profile

MORE
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead...
Corey Goodman Ph.D.
Chairman
Jaume Pons Ph.D.
President
Peter Garcia
Chief Financial Officer
Steffen Pietzke CPA
Chief Accounting Officer
Address
866 Malcolm Road, Suite 100
Burlingame, CA
94010
United States